The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Baricitinib Appears Effective in Biologic-Refractory RA

Baricitinib Appears Effective in Biologic-Refractory RA

March 27, 2018 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial.

You Might Also Like
  • Baricitinib Also Appears Effective in Biologic-Refractory RA
  • Baricitinib Effective for Treating Refractory Rheumatoid Arthritis
  • Baricitinib Has Promising Clinical Trial Results for Treating RA

The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical responses at Week 12 than placebo.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the current study, Mark C. Genovese, MD, from Stanford University Medical Center, in Palo Alto, Calif., and colleagues undertook exploratory, post hoc analyses to evaluate the effect of prior use of biologic disease-modifying antirheumatic drugs (bDMARDs) on the efficacy and safety of baricitinib.

For the primary endpoint, a 20% improvement in ACR20 at Week 12, there were no significant interactions based on the patient’s prior experience by the number of prior bDMARDS, the number of prior TNF inhibitors, the number of prior non-TNF inhibitor treatments or specific prior TNF inhibitor, the team reports in Rheumatology, online Feb. 3.¹

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Similarly, when evaluating ACR20 responses at Weeks 12 and 24 according to the patient’s last bDMARD before randomization, the researchers found that response rates for baricitinib were numerically higher than those for placebo regardless of which TNF inhibitor or non-TNF inhibitor was used, with the exception of 2 mg baricitinib vs. infliximab.

There was no increase in serious infections for either baricitinib dose according to prior biologic use, including for patients who had received multiple prior biologics.

“Baricitinib demonstrated a consistent, beneficial treatment effect in bDMARD-refractory patients across subgroups based on baseline characteristics and prior bDMARD use,” the researchers conclude. “Because the population of rheumatoid arthritis patients who are TNF-inhibitor inadequate responders is increasing, this finding may be clinically relevant.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Genovese did not respond to a request for comment.

Eli Lilly & Co. and Incyte sponsored the trial. Eli Lilly employed half of the authors and had various relationships with several others.


Reference
  1. Genovese MC, Kremer JM, Kartman CE, et al. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology (Oxford). 2018 Feb 3. doi: 10.1093/rheumatology/kex489. [Epub ahead of print]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: baricitinib, biologic-refractory RA

You Might Also Like:
  • Baricitinib Also Appears Effective in Biologic-Refractory RA
  • Baricitinib Effective for Treating Refractory Rheumatoid Arthritis
  • Baricitinib Has Promising Clinical Trial Results for Treating RA
  • Long-Term Data Show Baricitinib Is Safe & Effective for RA

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.